Source: National Law Review

The article explores the transformative impact of artificial intelligence on drug discovery, offering an outlook for 2025. AI is increasingly used to identify potential drug candidates, optimize clinical trials, and accelerate the development of personalized medicine. These advancements promise to reduce research timelines and costs while increasing efficiency in pharmaceutical innovation.

However, the integration of AI raises significant legal and ethical challenges. Issues such as intellectual property rights for AI-generated discoveries, data privacy in clinical trials, and compliance with medical regulations are highlighted as critical areas for policymakers and industry leaders.

The article also discusses the evolving role of regulatory bodies in overseeing AI applications in healthcare, emphasizing the need for clear guidelines to ensure patient safety and data integrity. Case studies of successful AI-driven drug developments underscore the potential of this technology to address global health crises.

The piece concludes by calling for collaboration between AI developers, healthcare professionals, and legal experts to establish a balanced framework that fosters innovation while addressing legal, ethical, and safety concerns.